Login to Your Account

Safety Issues Cited

FDA Review of Gout Drug Sends Savient Stock Soaring

By Donna Young

Monday, June 15, 2009
Shares of Savient Pharmaceuticals Inc. skyrocketed 56 percent Friday after FDA drug reviewers said in briefing documents that the firm's gout drug Krystexxa (pegloticase) was effective. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription